Sage Journals: Discover world-class research

Abstract

Objective

This study aimed to assess the association of the neutrophil-to-lymphocyte ratio (NLR) with the occurrence of venous thromboembolism (VTE) and arterial thrombosis (AT).

Methods

This was a retrospective cross-sectional study including 585 medical records obtained from all consecutive patients who were suspected of having thrombosis.

Results

The AT group had a higher neutrophil count and NLR and a lower lymphocyte count than the non-thrombosis group. Receiver operating characteristic curve analysis showed the ability of the NLR to predict the presence of AT. The cut-off value for the NLR was 4.44. No distinction was found in the NLR between the VTE and non-thrombosis groups. Regression analysis showed that a high NLR was an independent factor related to the presence of AT. Patients with an NLR ≥ 4.44 had a higher risk of AT than those with an NLR < 4.44 (odds ratio = 2.015, 95% confidence interval: 1.180–3.443).

Conclusion

A high NLR may be considered a predictive factor for the occurrence of AT, but an association with the presence of VTE was not found.

Keywords

Neutrophil-to-lymphocyte ratio venous thromboembolism arterial thrombosis thrombosis neutrophil lymphocyte

Introduction

Thrombosis, including venous thromboembolism (VTE) and arterial thrombosis (AT), is a disease with a high mortality and morbidity rate. Myocardial infarction and thrombotic stroke are the main types of AT and are the most common causes of morbidity and mortality. VTE, including deep venous thrombosis (DVT) and pulmonary embolism (PE), is also the most common vascular disease after acute myocardial infarction and thrombotic stroke.¹ In the 19th century, Rudolph Virchow experimentally showed that the development of thrombosis may be caused by damage to the blood vessels, irritation of the surrounding area, blood coagulation, and interruption of blood flow. His thesis formed Virchow’s triad, which was considered the mechanism of VTE and included endothelial injury, hypercoagulability, and stasis.² In contrast, because of the strong flow in the arterial system, coagulation factors do not play a major role in AT. Vessel wall damage (atheroschlerosis, hypertension, vascular anomalies) is considered a major risk factor for AT. This damage allows platelets to easily adhere and aggregate. Thus, platelet hyperactivity plays a role in the pathogenesis of AT.^3,4

Currently, the combination of stasis and hypercoagulability is considered crucial to the occurrence of VTE, while endothelial damage and platelets play a role in the development of atherosclerosis and AT. Atherosclerosis is a chronic inflammatory disease; therefore, the role of inflammation in the pathogenesis of AT has been better studied than that in VTE.^5–7 Therefore, the neutrophil count and neutrophil-to-lymphocyte ratio (NLR), which are considered indicators of inflammation, would theoretically be associated with AT rather than VTE.^1,8 However, inflammation has been gradually accepted as a mechanism of thrombus formation in the veins. Inflammation of the vein wall triggers the coagulation system through the induction of tissue factor.^7,9,10 Furthermore, recent studies have demonstrated the role of neutrophils in both VTE and AT through activation of neutrophil extracellular traps (NETs). NETs activate factor XII and increase tissue factor production, leading to activation of the intrinsic and extrinsic pathways, thus augmenting VTE. Some mouse model studies have demonstrated the role of NETs in VTE; however, clinical evidence is sparse.^11–14 Although the mechanism of NETs that contributes to VTE has been established, its activation in AT has not been investigated.¹¹ Several mouse model studies have indicated that NETs play a role in atherosclerosis.^15–17 Other clinical observational studies also confirmed that NETosis (the process during which neutrophils undergo programmed cell death and release NET) is associated with greater severity and the extent of coronary artery disease.^18,19

The NLR is a simple indicator related to inflammation, as well as NETs, and can be used to study VTE and AT. Although mouse model studies on the role of neutrophils and NETs in thrombosis exist, clinical evidence is lacking. Clinical studies have not satisfactorily determined the value of the NLR in relation to VTE. However, clinical studies on the value of the NLR in AT have mainly focused on coronary artery disease.^20–24 Therefore, we conducted this study to assess the association of the NLR with the occurrence of VTE and AT.

Materials and methods

Medical records

This was a retrospective cross-sectional study. Medical data were obtained from all consecutive patients who were suspected of having thrombosis at Bach Mai Hospital, Hanoi, Vietnam, from January to December 2021. Patients with previously diagnosed thrombosis were excluded. The patients were divided into three groups. Group 1 included patients with newly diagnosed VTE. Group 2 included patients with newly diagnosed AT. Group 3 included patients who were not confirmed to have thrombosis. The determination of thrombosis was performed by computed tomography scans, magnetic resonance imaging, or Doppler ultrasound. The Institutional Review Board of Hanoi Medical University waived the need for approval and patient consent because of the retrospective observational nature of the study and because all information was obtained from medical records. All patient details were deidentified.

Collected data

Peripheral blood cell indices including the hemoglobin level and white blood cell, neutrophil, lymphocyte, monocyte, and platelet counts were collected before starting treatment. Biomarkers such as fibrinogen and D dimer were also collected. Data on comorbidities, risk factors, and status, including smoking, overweight, contraception, immobility, cardiovascular disease, postoperative care, cancer, antiphospholipid syndrome, infections, diabetes, and dyslipidemia, were also collected.

Statistical analysis

Differences were compared between two groups: VTE vs. non-thrombosis and AT vs. non-thrombosis. Qualitative variables (sex, smoking, overweight, contraception, immobility, cardiovascular disease, postoperative care, cancer, antiphospholipid syndrome, infections, diabetes, and dyslipidemia) were analyzed using the χ² or Fisher’s test. Quantitative variables (hemoglobin level; white blood cell, neutrophil, lymphocyte, monocyte, and platelet counts; NLR, and fibrinogen and D dimer levels) were analyzed using an independent samples T-test or Mann–Whitney test according to their normal or nonnormal distribution. Quantitative variables were also compared between the thrombosis group (VTE + AT) and the non-thrombosis group, among the VTE subgroups (including DVT, PE, and other VTE), and between the AT subgroups (including thrombotic stroke and other AT). Data for three subgroups were analyzed using one-way analysis of variance for parametric data or the Kruskal–Wallis test for nonparametric data.

Receiver operating characteristic (ROC) curve analysis was performed to assess the ability of the NLR to predict the occurrence of thrombosis (VTE and AT). Regression analysis was used to examine the relationship between the cut-off value and the presence of thrombosis (VTE and AT). A value of P < 0.05 was considered statistically significant. The bias was controlled because no patient medical records were lost.

The study reporting conformed to the STROBE guideline.²⁵

Results

Patient characteristics

This retrospective study included medical records of 363 patients with thrombosis including 281 VTE patients (group 1), 82 AT patients (group 2), and 222 patients without thrombosis (group 3). The median ages of groups 1, 2, and 3 were 45, 46, and 41 years, respectively. There was a significant difference in age between the VTE and non-thrombosis group and between the AT and non-thrombosis group (P = 0.039 and 0.012, respectively).

Table 1 shows that patients 45 years or older had a higher rate of thrombosis (VTE or AT) than patients under 45 years of age (P = 0.002, 0001, respectively). The proportion of women in the VTE group was higher than that in the non-thrombosis group (P = 0.002). However, no significant differences were found in the comorbidities, risk factors, or status, including smoking, overweight, contraception, immobility, cardiovascular disease, postoperative care, cancer, antiphospholipid syndrome, infections, diabetes, and dyslipidemia, among the VTE, AT, and non-thrombosis groups (Table 1).

Table 1.

Comorbidities, risk factors, and status of patients.

Factor		Non thrombosisn (%)	Venous thromboembolismn (%)	Arterial thrombosisn (%)	P
Age	<45 years	136 (44.9)	134 (44.7)	33 (40.2)	P1 = 0.002 P2 = 0.001
Age	≥45 years	86 (38.7)	147 (52.3)	49 (59.8)	P1 = 0.002 P2 = 0.001
Sex	Male	133 (59.9)	139 (49.5)	54 (65.9)	P1 = 0.02P2 > 0.05
Sex	Female	89 (40.1)	142 (50.5)	28 (34.1)	P1 = 0.02P2 > 0.05
Smoking	Yes	10 (4.5)	14 (5.0)	4 (4.9)	P1, P2 > 0.05
Smoking	No	212 (95.5)	267 (95)	78 (95.1)	P1, P2 > 0.05
Overweight	Yes	1 (0.4)	1 (0.4)	0 (0.0)	P1, P2 > 0.05
Overweight	No	221 (99.6)	280 (99.6)	82 (100)	P1, P2 > 0.05
Contraception	Yes	7 (3.2)	14 (5.0)	1 (1.2)	P1, P2 > 0.05
Contraception	No	215 (96.8)	273 (97.2)	81 (98.8)	P1, P2 > 0.05
Immobility	Yes	8 (3.6)	7 (2.5)	1 (1.2)	P1, P2 > 0.05
Immobility	No	214 (96.4)	273 (97.5)	81 (98.8)	P1, P2 > 0.05
Cardiovascular disease	Yes	61 (27.5)	77 (27.5)	26 (31.7)	P1, P2 > 0.05
Cardiovascular disease	No	161 (72.5)	203 (72.5)	56 (68.3)	P1, P2 > 0.05
Postoperation	Yes	23 (10.4)	26 (9.3)	14 (17.1)	P1, P2 > 0.05
Postoperation	No	199 (89.6)	254 (90.7)	68 (82.9)	P1, P2 > 0.05
Infection	Yes	44 (19.8)	42 (15)	20 (24.4)	P1, P2 > 0.05
Infection	No	178 (80.2)	238 (85)	62 (75.6)	P1, P2 > 0.05
Cancer	Yes	11 (5.0)	14 (5.0)	1 (1.2)	P1, P2 > 0.05
Cancer	No	211 (95)	266 (95.0)	81 (98.8)	P1, P2 > 0.05
Anti phospholipid syndrome	Yes	19 (8.6)	21 (7.5)	4 (4.9)	P1, P2 > 0.05
Anti phospholipid syndrome	No	203 (91.4)	259 (92.5)	78 (95.1)	P1, P2 > 0.05
Diabetes	Yes	19 (8.6)	30 (10.7)	9 (11.0)	P1, P2 > 0.05
Diabetes	No	203 (91.4)	252 (89.3)	73 (89.0)	P1, P2 > 0.05
Dyslipidemia	Yes	9 (4.1)	12 (4.3)	6 (7.3)	P1, P2 > 0.05
Dyslipidemia	No	213 (95.9)	270 (95.7)	76 (92.7)	P1, P2 > 0.05

Note: P1: between the venous thromboembolism and non-thrombosis groups.

P2: between the arterial thrombosis and non-thrombosis groups.

The location and type of thrombosis are presented in Table 2. The VTE subgroups included DVT, PE, and other thrombosis, in which the rate of DVT in the lower extremities was highest (41.0%). The AT subgroups included thrombotic stroke and other thrombosis, in which the rates of thrombotic stroke and AT in the lower extremities were highest (both 20.8%).

Table 2.

Location of thrombosis.

Venous thromboembolism			Arterial thrombosis
Location of thrombosis		n (%)	Location of thrombosis		n (%)
Deep venous thrombosis	Upper extremities	6 (2.2)	Thrombotic stroke (brain)		16 (20.8)
Deep venous thrombosis	Lower extremities	111 (41.0)
Pulmonary embolism		3 (1.1)
Venous thromboembolism in other locations	Retina	4 (1.5)	Arterial thrombosis in other locations	Retina	2 (2.6)
	Transverse sinuses	30 (11.1)		Transverse sinuses	2 (1.3)
	Spleen	8 (3.0)		Spleen	2 (2.6)
	Kidney	3 (1.1)		Kidney	7 (9.1)
	Mesentery	16 (5.9)		Mesentery	3 (3.9)
	Heart	8 (3.0)		Heart	2 (2.6)
	Brain	82 (30.3)		Upper extremities	4 (5.2)
	Brain	82 (30.3)		Lower extremities	16 (20.8)

Table 3 shows that the AT group had a higher neutrophil count and NLR and a lower lymphocyte count (P < 0.05) than the non-thrombosis group. However, these differences were not observed when comparing the VTE group with the non-thrombosis group and the thrombosis (VTE + AT) group with the non-thrombosis group. The D dimer and fibrinogen levels in the AT group and the thrombosis group (VTE + AT) were significantly higher than that in the non-thrombosis group (P < 0.05). A significant difference was only observed in the D dimer index when comparing the VTE group with the non-thrombosis group (P = 0.041).

Table 3.

Peripheral blood cell and biomarker indices.

Indices	Non-thrombosis	Thrombosis (VTE + AT)	VTE	AT	P
Hemoglobin (g/L)(Mean ± SD)	131.04 ± 26.08	130.61 ± 25.03	129.02 ± 25.22	135.95 ± 23.75	P1, P2, P3 > 0.05
WBCs (×10⁹/L)(Median)	10.3	10.86	10.39	11.46	P1, P2, P3 > 0.05
Neutrophils (×10⁹/L)(Median)	7.57	7.6	7.32	9.36	P1, P3 > 0.05P2 = 0.006
Lymphocytes (×10⁹/L)(Median)	1.5	1.71	1.81	1.35	P1, P3 > 0.05P2 = 0.015
Monocytes (×10⁹/L)(Median)	0.71	0.73	0.72	0.79	P1, P2, P3 > 0.05
Platelets (×10⁹/L)(Median)	241	230	247	217	P1, P2, P3 > 0.05
NLR(Median)	4.39	4.17	3.87	6.8	P1, P3 > 0.05P2 < 0.001
Fibrinogen (g/L)(Mean ± SD)	3.74 ± 1.51	4.06 ± 1.5	4.00 ± 1.43	4.25 ± 1.68	P1 > 0.05P2 = 0.034P3 = 0.037
D dimer (mg/L FEU)(Median)	2.08	3.6	3.46	6.11	P1 = 0.041 P2 = 0.034 P3 = 0.018

VTE, venous thromboembolism; AT, arterial thrombosis; SD, standard deviation; WBCs, white blood cells, NLR, neutrophil-to-lymphocyte ratio; FEU, fibrinogen equivalent units.

Note: P1: between the VTE and non-thrombosis groups.

P2: between the AT and non-thrombosis groups.

P3: between the thrombosis (including VTE and AT) and non-thrombosis groups.

The results also indicate that there were no differences among the VTE subgroups or between the AT subgroups when comparing the laboratory indices, except for the hemoglobin level (P < 0.001 for the VTE subgroups) and monocyte count (P < 0.001 for the AT subgroups) (Table 4).

Table 4.

Peripheral blood cell and biomarker indices according to the type of VTE or AT.

Indices	VTE			AT		P
Indices	DVT	PE	Other VTE	TS	Other AT	P
Hemoglobin (g/L)(Mean ± SD)	122.56 ± 25.35	117.33 ± 39.4	134.82 ± 21.20	142.75 ± 20.53	135.25 ± 23.24	P1 < 0.001P2 > 0.05
WBCs (×10⁹/L) (Median)	9.63	13.75	10.9	9.63	11.72	P1, P2 > 0.05
Neutrophils (×10⁹/L)(Median)	6.58	10.55	7.71	7.71	9.5	P1, P2 > 0.05
Lymphocytes (×10⁹/L)(Median)	1.81	1.56	1.81	1.29	1.39	P1, P2 > 0.05
Monocytes (×10⁹/L)(Median)	0.71	0.66	0.77	0.63	0.85	P1 > 0.05P2 < 0.001
Platelets (×10⁹/L)(Median)	244	246	248	231	200	P1, P2 > 0.05
NLR(Median)	3.44	4.61	4.11	7.59	7.0	P1, P2 > 0.05
Fibrinogen (g/L) (Mean ± SD)	3.8 ± 1.35	3.83 ± 1.12	4.16 ± 1.42	3.86 ± 0.95	4.34 ± 1.87	P1, P2 > 0.05
D dimer (mg/L FEU) (Median)	4.66	7.65	3.41	4.30	6.15	P1, P2 > 0.05

VTE, venous thromboembolism; AT, arterial thrombosis; SD, standard deviation; WBCs, white blood cells, NLR, neutrophil-to-lymphocyte ratio; FEU, fibrinogen equivalent units; DVT, deep venous thrombosis; PE, pulmonary embolism; TS, thrombotic stroke.

Note: P1: among the VTE, PE, and other VTE groups.

P2: between the TS and other AT groups.

ROC curve analysis for the NLR

ROC curve analysis showed the ability of the NLR to predict the presence of AT. The area under the curve for the NLR was 64.1% with P < 0.001 (Figure 1, Table 5). Based on the sensitivity and specificity analysis, the cut-off value of the NLR was determined to be 4.44 (Table 5). However, this analysis did not indicate an NLR value that could distinguish VTE from non-thrombosis.

Figure 1.

Receiver operating characteristic curve analysis of the ability of the neutrophil-to-lymphocyte ratio to distinguish between the arterial thrombosis and non-thrombosis groups.

Table 5.

Receiver operating characteristic curve analysis of the ability of the neutrophil-to-lymphocyte ratio to predict the presence of arterial thrombosis.

AUC	P	Cut-off value	Sensitivity (%)	Specificity (%)
0.641	<0.001	4.44	60.3	60.2

AUC, area under the receiver operating characteristic curve.

Regression analysis of the NLR

The regression analysis showed that a high NLR (≥4.44) and older age (≥45 years) were independent factors related to the presence of AT (Table 6). Patients with a high NLR (≥4.44) had a higher risk of AT than those with an NLR < 4.44 (odds ratio = 2.015, 95% confidence interval: 1.180–3.443, P = 0.01).

Table 6.

Association of the NLR with VTE and AT.

Factor		VTE				AT
		Univariate analysis	Multivariate analysis			Univariate analysis	Multivariate analysis
		P	P	OR	95% CI	P	P	OR	95% CI
NLR	<4.44	>0.05				0.006	0.01	2.015	1.180–3.443
NLR	≥4.44	>0.05				0.006	0.01	2.015	1.180–3.443
Age (years)	<45	0.002	0.002	1.746	1.219–2.501	0.001	0.004	2.194	1.286–3.741
Age (years)	≥45	0.002	0.002	1.746	1.219–2.501	0.001	0.004	2.194	1.286–3.741
Sex	Male	0.02	0.019	1.539	1.074–2.205	>0.05
Sex	Female	0.02	0.019	1.539	1.074–2.205	>0.05

VTE, venous thromboembolism; AT, arterial thrombosis; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; CI, confidence interval.

The regression analysis also indicated that older age (≥45 years) and sex (female) were independent factors related to the presence of VTE (Table 6).

Discussion

Mouse model studies have shown the role of inflammation and NETs in both VTE and AT. Although the NLR is considered a biomarker of inflammation, whether the NLR is a simple index that represents inflammation or NETs in relation to VTE and AT and the scope of its clinical application are unknown. These questions require further research.

Clinical observational studies have shown differing results. Cavuş et al. and Köse et al. suggested that the NLR is an independent prognostic factor for pulmonary embolism.^26,27 Zhao et al. also indicated that the NLR can be used as a marker to predict outcomes in patients after cerebral venous thrombosis treatment.²⁸ However, the more interesting value of the NLR is whether it can be considered a diagnostic marker or predictor of the occurrence of VTE. Grimnes et al. determined that the NLR was not associated with the risk of first time or recurrent VTE.²⁰ Artoni et al. also suggested that a high NLR was not related to an increased risk of VTE.²¹ In contrast, Rinaldi et al. and Hu et al. found that a high NLR can be considered a diagnostic marker for VTE.^22,29 Additionally, Farah et al. claimed that a high NLR could be a predictor of acute VTE.³⁰ Some studies indicated that a high NLR may be a trigger that increases the risk of VTE in comorbidity. Studies by Carobbio et al., including patients with polycythemia vera, and Peng et al., including patients after oral cancer surgery, indicated that a high NLR can increase the risk of VTE.^31,32 However, Yao et al. and Niu et al. did not find this association in patients after total joint arthroplasty or after femoral neck fractures.^33,34 Similar to Grimnes et al. and Artoni et al., our study did not find an association between a high NLR and the occurrence of VTE. In our study, only older age (≥45 years) and sex (female) were related to the presence of VTE. Furthermore, no differences were found among the VTE subgroups (DVT, PE, and other VTE), with the exception of the hemoglobin level. Some studies have indicated that a high hemoglobin level is a risk factor for VTE; however, no study has shown a difference between VTE subgroups.^35–37 In general, studies on the value of a high NLR in increasing the risk of VTE are controversial. There is still a long distance from mouse model study results to their clinical application.

Unlike in patients with VTE, a high NLR was closely associated with the occurrence of AT. Our study showed that patients with AT had a higher NLR than patients without thrombosis (P < 0.05). Multivariate regression analysis showed that patients with a high NLR (4.44) had a 2-fold higher risk of AT than those with an NLR < 4.44. Mouse model studies of Lee et al. and Cha et al. determined that leukocytosis and neutrophilia play a role in the development of AT.^38,39 Laridan et al. analyzed thrombi from ischemic stroke patients and suggested that neutrophils and NETs are important constituents of cerebral thrombi.⁴⁰ Several clinical observational studies have also supported that a high NLR is associated with AT; however, these studies were associated with coronary artery disease. Sönmez et al. and Kaya et al. showed that a high NLR (2.3 to 2.6) was considered an independent factor in the severity prognosis of patients with coronary artery disease. Kaya et al. also indicated that a high NLR is a predictor of severe atherosclerosis.^23,24 Papa et al. suggested that the NLR is an independent predictor of cardiac death.⁴¹ These results focused on the prognostic value of the NLR. More importantly, Angkananard et al. assumed that the NLR may be a useful biomarker of cardiovascular disease; therefore, it should be examined when assessing cardiovascular risk in the population.⁴² Moreover, in a rare study of other arteries, Chung et al. suggested that this association depended on the type of artery. This study indicated that a high NLR is related to a large cerebral artery with atherosclerosis, but it is not related to a small cerebral vessel.⁴³ However, the formation of thrombosis is related to many factors. Unfortunately, in our study, the arteries were not grouped according to size. However, when comparing between thrombotic stroke and other AT, no differences were found, except for the monocyte count. Monocytes can contribute to the development of thrombosis because of the release of pro-inflammatory cytokines, and they can interact with platelets and endothelial cells. The role of monocytes in the pathogenesis of thrombosis is recognized; however, few studies have focused on the differences between AT subgroups.⁴⁴

Inflammation and NETs have been associated with thrombosis (VTE and AT). Studies were carried out to examine whether a high NLR may be a predictor of thrombosis. However, it is not yet possible to confirm whether the activity of NETs correlates with a high NLR. Additional research is needed to answer this question.

Our study also showed that D dimer levels in the AT, VTE, and thrombosis groups were higher than that in the non-thrombosis group (P < 0.05). D dimer is a fibrin degradation product and is an important marker for the diagnosis of thrombosis, such as PE. However, for the purpose of this study, we do not discuss this topic.

Limitations of our study

The sample size of the AT group was small, less than one-third of that of the VTE group and the non-thrombosis group. This was a cross-sectional study; therefore, the non-thrombosis group was not followed up. We were unable to assess whether progression of thrombosis occurred in this group.

Conclusion

Our study indicates that the NLR is associated with the occurrence of AT. A high NLR may increase the risk of AT. This significance was not found for VTE. The value of the NLR in thrombosis remains an open question. Additional research is needed to determine how this index can be used effectively, its purpose (diagnosis, prediction, prognosis, indication of treatment), and the type of thrombosis (VTE, AT, type of artery) for which it can be used.

Supplemental Material

sj-pdf-1-imr-10.1177_03000605241240999 - Supplemental material for Association of the neutrophil-to-lymphocyte ratio with the occurrence of venous thromboembolism and arterial thrombosis

Supplemental material, sj-pdf-1-imr-10.1177_03000605241240999 for Association of the neutrophil-to-lymphocyte ratio with the occurrence of venous thromboembolism and arterial thrombosis by Ha Thanh Nguyen, Minh Phuong Vu, Thi Tuyet Mai Nguyen, Tuan Tung Nguyen, Thi Van Oanh Kieu, Hai Yen Duong, Phuong Thao Pham and Thi Hue Hoang in Journal of International Medical Research

Footnotes

Acknowledgements

The authors thank all technicians of the Morpho-histological Lab, Hematology and Blood Transfusion Center, Bach Mai Hospital, for their efforts in supporting this research.

Author contributions

Ha Thanh Nguyen: Data curation, Formal analysis, Methodology, Writing; Minh Phuong Vu: Conceptualization, Data curation, Formal analysis, Methodology, Writing; Thi Tuyet Mai Nguyen: Data curation, Formal analysis, Investigation, Writing; Tuan Tung Nguyen: Formal analysis, Methodology, Writing; Thi Van Oanh Kieu: Formal analysis, Investigation, Writing; Hai Yen Duong: Formal analysis, Investigation, Writing; Phuong Thao Pham: Formal analysis, Investigation, Writing; Thi Hue Hoang: Formal analysis, Investigation, Writing. All authors have read and approved the final manuscript.

Declaration of conflicting interests

The authors declare that there is no conflict of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Minh Phuong Vu

References

Previtali

Bucciarelli

Passamonti

, et al. Risk factors for venous and arterial thrombosis. Blood Transfus 2011; 9: 120–138. doi: 10.2450/2010.0066-10. Epub 2010 Oct 25. PMID: 21084000; PMCID: PMC3096855.

Stone

Hangge

Albadawi

, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther 2017; 7: S276–S284. doi: 10.21037/cdt.2017.09.01. PMID: 29399531; PMCID: PMC5778510.

Lippi

Franchini

Targher

Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 2011; 8: 502–512. doi: 10.1038/nrcardio.2011.91. PMID: 21727917.

Wang

LM.

New understanding on the pathogenesis of acute arterial thrombosis. J Geriatr Cardiol 2015; 12: 204–207. doi: 10.11909/j.issn.1671-5411.2015.03.023. PMID: 26089842; PMCID: PMC4460161.

Kobiyama

Ley

Atherosclerosis. Circ Res 2018; 123: 1118–1120. doi: 10.1161/CIRCRESAHA.118.313816. PMID: 30359201; PMCID: PMC6298754.

Taleb

Inflammation in atherosclerosis. Arch Cardiovasc Dis 2016; 109: 708–715. doi: 10.1016/j.acvd.2016.04.002. Epub 2016 Aug 29. PMID: 27595467.

Poredos

Jezovnik

MK.

The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. Int Angiol 2007; 26: 306–311. PMID: 18091697.

Zahorec

Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy 2021; 122: 474–488. doi: 10.4149/BLL_2021_078. PMID: 34161115.

Branchford

Carpenter

SL.

The role of inflammation in venous thromboembolism. Front Pediatr 2018; 6: 142. doi: 10.3389/fped.2018.00142. PMID: 29876337; PMCID: PMC5974100.

10.

Colling

Tourdot

Kanthi

Inflammation, infection and venous thromboembolism. Circ Res 2021; 128: 2017–2036. doi: 10.1161/CIRCRESAHA.121.318225. Epub 2021 Jun 10. PMID: 34110909; PMCID: PMC8202069.

11.

Kapoor

Opneja

Nayak

The role of neutrophils in thrombosis. Thromb Res 2018; 170: 87–96. doi: 10.1016/j.thromres.2018.08.005. Epub 2018 Aug 9. PMID: 30138777; PMCID: PMC6174090.

12.

Thålin

Hisada

Lundström

, et al. Neutrophil extracellular traps: villains and targets in arterial, venous, and cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 2019; 39: 1724–1738. doi: 10.1161/ATVBAHA.119.312463. Epub 2019 Jul 18. PMID: 31315434; PMCID: PMC6703916.

13.

Laridan

Martinod

De Meyer

SF.

Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost 2019; 45: 86–93. doi: 10.1055/s-0038-1677040. Epub 2019 Jan 11. PMID: 30634198.

14.

Von Brühl

Stark

Steinhart

, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819–835. doi: 10.1084/jem.20112322. Epub 2012 Mar 26. PMID: 22451716; PMCID: PMC3328366.

15.

Josefs

Barrett

Brown

, et al. Neutrophil extracellular traps promote macrophage inflammation and impair atherosclerosis resolution in diabetic mice. JCI Insight 2020; 5: e134796. doi: 10.1172/jci.insight.134796. PMID: 32191637; PMCID: PMC7205252.

16.

Warnatsch

Ioannou

Wang

, et al. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 2015; 349: 316–320. doi: 10.1126/science.aaa8064. Epub 2015 Jul 16. PMID: 26185250; PMCID: PMC4854322.

17.

Drechsler

Megens

Van Zandvoort

, et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010; 122: 1837–1845. doi: 10.1161/CIRCULATIONAHA.110.961714. Epub 2010 Oct 18. PMID: 20956207.

18.

Bonaventura

Vecchié

Abbate

, et al. Neutrophil extracellular traps and cardiovascular diseases: an update. Cells 2020; 9: 231. doi: 10.3390/cells9010231. PMID: 31963447; PMCID: PMC7016588.

19.

Borissoff

Joosen

Versteylen

, et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 2013; 33: 2032–2040. doi: 10.1161/ATVBAHA.113.301627. Epub 2013 Jul 1. PMID: 23818485; PMCID: PMC3806482.

20.

Grimnes

Horvei

Tichelaar

, et al. Neutrophil to lymphocyte ratio and future risk of venous thromboembolism and mortality: the Tromsø Study. Haematologica 2016; 101: e401–e404. doi: 10.3324/haematol.2016.145151. Epub 2016 Jun 13. PMID: 27479821; PMCID: PMC5046660.

21.

Artoni

Abbattista

Bucciarelli

, et al. Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio as risk factors for venous thrombosis. Clin Appl Thromb Hemost 2018; 24: 808–814. doi: 10.1177/1076029617733039. Epub 2017 Oct 31. PMID: 29088921; PMCID: PMC6714878.

22.

Rinaldi

Hamonangan

Azizi

, et al. Diagnostic value of neutrophil lymphocyte ratio and d-dimer as biological markers of deep vein thrombosis in patients presenting with unilateral limb edema. J Blood Med 2021; 12: 313–325. https://doi.org/10.2147/JBM.S291226.

23.

Sönmez

Ertaş

Bacaksız

, et al. Relation of neutrophil-to-lymphocyte ratio with the presence and complexity of coronary artery disease: an observational study. Anadolu Kardiyol Derg 2013; 13: 662–667. doi: 10.5152/akd.2013.188. Epub 2013 Jul 31. PMID: 23912788.

24.

Kaya

Ertaş

İslamoğlu

, et al. Association between neutrophil to lymphocyte ratio and severity of coronary artery disease. Clin Appl Thromb Hemost 2014; 20: 50–54. doi: 10.1177/1076029612452116. Epub 2012 Jul 11. PMID: 22790659.

25.

Von Elm

Altman

Egger

, STROBE Initiativeet al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344–349. doi: 10.1016/j.jclinepi.2007.11.008. PMID: 18313558.

26.

Cavuş

Yildirim

Sönmez

, et al. Prognostic value of neutrophil/lymphocyte ratio in patients with pulmonary embolism. Turk J Med Sci 2014; 44: 50–55. PMID: 25558558.

27.

Köse

Yıldırım

Akın

, et al. Prognostic role of NLR, PLR, and LMR in patients with pulmonary embolism. Bosn J Basic Med Sci 2020; 20: 248–253. doi: 10.17305/bjbms.2019.4445. PMID: 31724521; PMCID: PMC7202190.

28.

Zhao

Liu

, et al. Neutrophil-to-lymphocyte ratio predicts the outcome of cerebral venous thrombosis. Curr Neurovasc Res 2021; 18: 204–210. doi: 10.2174/1567202618666210726122310. PMID: 34313199.

29.

Cai

Zhou

The association of neutrophil-lymphocyte ratio with venous thromboembolism: a systematic review and meta-analysis. Clin Appl Thromb Hemost 2022; 28: 10760296221130061. doi: 10.1177/10760296221130061. PMID: 36189877; PMCID: PMC9530558.

30.

Farah

Nseir

Kagansky

, et al. The role of neutrophil-lymphocyte ratio, and mean platelet volume in detecting patients with acute venous thromboembolism. J Clin Lab Anal 2020; 34: e23010. doi: 10.1002/jcla.23010. Epub 2019 Sep 11. PMID: 31508844; PMCID: PMC6977138.

31.

Carobbio

Vannucchi

De Stefano

, et al. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J 2022; 12: 28. doi: 10.1038/s41408-022-00625-5. PMID: 35145055; PMCID: PMC8831521.

32.

Peng

Bao

Hong

, et al. High level of neutrophil to lymphocyte ratio increases the risk of deep venous thrombosis in intensive care unit patients after oral cancer surgery: a retrospective study. Ann Transl Med 2022; 10: 763. doi: 10.21037/atm-22-2453. PMID: 35965831; PMCID: PMC9372679.

33.

Yao

Zhang

Yao

, et al. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio for acute deep vein thrombosis after total joint arthroplasty: a retrospective study. J Orthop Surg Res 2018; 13: 40. doi: 10.1186/s13018-018-0745-x. PMID: 29482566; PMCID: PMC5828483.

34.

Niu

Pei

, et al. Relationship between the neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio and deep venous thrombosis (DVT) following femoral neck fractures in the elderly. Front Surg 2022; 9: 1001432. doi: 10.3389/fsurg.2022.1001432. PMID: 36311921; PMCID: PMC9606705.

35.

Xiong

, et al. Association between red blood cell indices and preoperative deep vein thrombosis in patients undergoing total joint arthroplasty: a retrospective study. Clin Appl Thromb Hemost 2022; 28: 10760296221149029. doi: 10.1177/10760296221149029. PMID: 36572965; PMCID: PMC9806375.

36.

Folsom

Wang

Parikh

; Atherosclerosis Risk in Communities (ARIC) Study Investigatorset al. Hematocrit and incidence of venous thromboembolism. Res Pract Thromb Haemost 2020; 4: 422–428. doi: 10.1002/rth2.12325. PMID: 32211576; PMCID: PMC7086464.

37.

Cushman

Wang

Parikh

, et al. Hematocrit and incidence of venous thromboembolism. Blood 2019; 134: 1142–1142. doi: https://doi.org/10.1182/blood-2019-124126.

38.

Lee

Kwon

Nam

, et al. Effect of leukopenia induced by cyclophosphamide on the initial stage of arterial thrombosis in mice. Thromb Res 2021; 206: 111–119. doi: 10.1016/j.thromres.2021.08.017. Epub 2021 Aug 24. PMID: 34455128.

39.

Cha

Lee

, et al. Neutrophil recruitment in arterial thrombus and characteristics of stroke patients with neutrophil-rich thrombus. Yonsei Med J 2022; 63: 1016–1026. doi: 10.3349/ymj.2022.0328. PMID: 36303310; PMCID: PMC9629897.

40.

Laridan

Denorme

Desender

, et al. Neutrophil extracellular traps in ischemic stroke thrombi. Ann Neurol 2017; 82: 223–232. doi: 10.1002/ana.24993. Epub 2017 Aug 11. PMID: 28696508.

41.

Papa

Emdin

Passino

, et al. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta 2008; 395: 27–31. doi: 10.1016/j.cca.2008.04.019. Epub 2008 May 1. PMID: 18498767.

42.

Angkananard

Anothaisintawee

McEvoy

, et al. Neutrophil lymphocyte ratio and cardiovascular disease risk: a systematic review and meta-analysis. Biomed Res Int 2018; 2018: 2703518. doi: 10.1155/2018/2703518. PMID: 30534554; PMCID: PMC6252240.

43.

Chung

Lee

Choi

, et al. Blood neutrophil/lymphocyte ratio is associated with cerebral large-artery atherosclerosis but not with cerebral small-vessel disease. Front Neurol 2020; 11: 1022. doi: 10.3389/fneur.2020.01022. PMID: 33013672; PMCID: PMC7509145.

44.

Han

Liu

, et al. The role of monocytes in thrombotic diseases: a review. Front Cardiovasc Med 2023; 10: 1113827. doi: 10.3389/fcvm.2023.1113827. PMID: 37332592; PMCID: PMC10272466.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.22 MB